Moreover, in 2021, the FeDeriCa trial demonstrated that pertuzumab + trastuzumab + hyaluronidase in the subcutaneous injection of patients with HER2-positive early breast cancer could significantly shorten the administration time with similar pathological complete response rate and pharmacokinetic characteristics to intravenous preparation [48]. Here, ERBB2 is linked to breast carcinoma.